

# Rare complication of primary infection with Epstein-Barr virus: a case report and short review of literature

Katja Jarc Georgiev,<sup>1</sup> Tina Ahačič,<sup>2</sup> Peter Najdenov<sup>2</sup>

<sup>1</sup> Community health centre Škofja Loka, Škofja Loka, Slovenia

<sup>2</sup> Children's Ward, Jesenice general hospital, Jesenice, Slovenia

## Correspondence:

Katja Jarc Georgiev,  
e: katja.jarc@gmail.com

## Key words:

infectious mononucleosis; acute acalculous cholecystitis; Epstein-Barr virus

Received: 6. 3. 2018

Accepted: 5. 12. 2018

## Abstract

Acute acalculous cholecystitis (AAC) is a rare complication of primary infection with Epstein-Barr virus (EBV). A 17-year old male was admitted to the hospital due to abdominal pain, severe vomiting, tonsillitis and splenomegaly. Infectious mononucleosis was suspected and confirmed using agglutination test to detect heterophile antibodies IgM against EBV. Ultrasonography showed thickened and stratified gallbladder wall with no gallstones. Full recovery following conservative therapy with a broad-spectrum antibiotic, analgesic and rehydration therapy was noted. To our knowledge, this is the first case of EBV related AAC in the Slovenian medical literature. AAC is a possible severe complication of infection with EBV and should be taken into consideration in cases of EBV infection presenting with severe abdominal pain.

**Cite as:** Jarc Georgiev K, Ahačič T, Najdenov P. [Rare complication of primary infection with Epstein-Barr virus: case report and short review of literature]. *Zdrav Vestn.* 2019;88(5-6):276-81.

**DOI:** 10.6016/ZdravVestn.2821

## 1 Introduction

Acute acalculous cholecystitis (AAC) is an acute disease of the gallbladder in the absence of gallstones (1). Unlike in adults, where it accounts for only 5–10 % of cases, AAC is the most common form of acute cholecystitis in children (50–70 % of cases) (1,2). Although it is mostly described in literature as a complication of severe trauma or burns, severe systemic disease (Mb. Kawasaki, systemic lupus eritematosus, nephrotic syndrome), complete parenteral nutrition or severe dehydration, it is most often the effect, in immunocompetent paediatric population, of infection with

different organisms (1,3,4). AAC development both in adults and children has been noted following infection with bacteria (*Brucella* spp., *Campylobacter jejuni*, *Coxiella burnetii*, *Leptospira* spp, *Mycobacterium* spp., *Salmonella* spp and *Vibrio cholerae*), fungi (*Candida* spp), viruses (hepatitis A and B viruses – HAV, HBV, Epstein-Barr virus – EBV, cytomegalovirus – CMV and flavivirus) and parasites (*Plasmodium* spp, *Ascaris lumbricoides* and *Echinococcus*); of which infections with EBV and HAV are described the most often (1,5). The article

presents a case of AAC following primary EBV infection.

## 2 Case presentation

A seventeen year old male was admitted following 14 days of nausea, fatigue and decreased appetite. On the day of admission, the patient began to complain about epigastric pain, which responded poorly to treatment with pantoprazole and metamizole. The patient had previously been healthy and had not been receiving any medication. Upon admission, the patient looked tired and pale, had no temperature, had mild pharyngitis and no signs of tonsillitis. The abdomen was at chest level and very sensitive to touch in the area of xiphoid process and upper right quadrant, while the liver and spleen were not enlarged to touch. Upon auscultation, peristaltic action was observed in all four quadrants. Otherwise, physical status was normal. Laboratory reports showed mild leucocytosis ( $13.70 \times 10^9/L$  in differential blood count, with 78 % lymphocytes, 4 % monocytes, 3 % banded neutrophils, 15 % segmented neutrophils) and mildly elevated values of C-reactive protein 5.1 mg/L (reference range (RR) 0–3.5 mg/L). Electrolyte and blood urea nitrogen values were within normal range. The patient was first treated for acute inflammation of the stomach lining. Parenteral therapy with H<sub>2</sub> receptor antagonist and analgesics was introduced, and the patient was put on gastric diet. The second day of hospitalisation the pain began to escalate, and the patient began to vomit. Clinically, enlarged and hyperemic tonsils with spots, and an enlarged spleen was noted. Follow-up laboratory reports showed elevated values of total bilirubin 63  $\mu\text{mol/L}$  (RV:3–17  $\mu\text{mol/L}$ ), and direct bilirubin 42  $\mu\text{mol/L}$  (RR: 0–3  $\mu\text{mol/L}$ ), aspartate aminotransferase

9.23  $\mu\text{kat/L}$  (RR: 0.01–0.58  $\mu\text{kat/L}$ ), alanine aminotransferase 16.48  $\mu\text{kat/L}$  (RR: 0.01–0.74), gamma glutamyl transferase 5.00  $\mu\text{kat/L}$  (RR 0.03–0.70  $\mu\text{kat/L}$ ), amylase 3.53  $\mu\text{kat/L}$  (RR: 0.01–1.92  $\mu\text{kat/L}$ ) and lipase 21.73  $\mu\text{kat/L}$  (RR: 1.21–6.55  $\mu\text{kat/L}$ ).

Extensive microbiological testing was performed to look for pathological values of liver enzymes. Rapid agglutination test based on Paul Brunel was used to detect the presence of IgM heterophile antibodies to EBV (PB-HA), which mostly indicate acute infection with EBV. CMV antibody titres were also elevated, which was established using (*angl.* Chemiluminescence Assay (CLIA), with IgM: 33.2 U/ml, IgG: 129.00 U/ml. Rapid step test from a pharynx swab was negative. Possible infection with HAV and HCV was excluded. When testing for hepatitis b viral infection (HBV), HBV surface antigen (HBs Ag) was negative, while IgG antibodies to HBV surface antigen (anti HBs) were positive, which is consistent with an immune response following vaccination. Haemocultures were sterile. A stool sample was taken to detect the presence of Helicobacter pylori antigen using *angl.* Enzyme-Linked Immunosorbent Assay, ELISA.

Ultrasound (US) of the abdomen was performed, which showed contracted gallbladder with striated thickened wall (1–1.5 cm), and a small amount of free fluid by the liver. Although the sonography of the gallbladder was not clear, there were no signs of hardened deposits and the ducts were not dilated. The spleen was enlarged and palpable, with a diameter of up to 16 cm, with lymph nodes in the upper part of the abdomen enlarged too. The original therapy was continued and an antiemetic agent added (setronone). The US was repeated the fourth day of hospitalisation, when the diagnosis of AAC was confirmed.

After consulting surgeons, conservative treatment was continued and antibiotic therapy with amoxicillin combined with clavulanic acid introduced. The patient's general condition improved, the pain and tonsillitis went away, and laboratory testing noted a drop in the values of liver enzymes. The tenth day of hospitalisation the patient was released into home care and prescribed oral antibiotic. US before release revealed a normal gallbladder without visible pathological changes. Three months after the end of hospitalisation the patient had appropriate physical ability, and biochemical values of liver function were within the normal range.

Due to positive HP antigen in the stool, triple therapy with clindamycin, amoxicillin and proton pump inhibitor was introduced following the end of treatment with amoxicillin and clavulanic acid. The follow-up stool sample, tested for HP antigen 8 weeks after eradication treatment was negative.

### 3 Discussion

AAC is a rare complication of primary EBV infection. Since 2000, 23 cases have been described among pediatric population (6-26), most of them in Europe, of which seven were described in Greece (7,8,11-13,20). This article is the first presentation of AAC linked to EBV based on a clinical case in Slovene medical literature.

AAC has diverse and non-specific clinical presentation. Most common clinical symptoms in children are fever and abdominal pain (1). Like in most other described cases, the reason that prompted a visit to the physician was abdominal pain. Upon admission, while the patient had mild pharyngitis, he lacked typical clinical presentation of infectious mononucleosis (IM) with generalised lym-

phadenopathy and fever (12). Only splenomegaly and tonsillitis with spots that manifested on the second day of hospitalisation led us to suspect infection with EBV infection. The patient also reported early signs of IM, including nausea, fatigue and decreased appetite, which had appeared 14 days earlier together with abdominal pain.

Although US criteria for diagnosing AAC remain unspecific, the following descriptions are most often reported in literature: absence of gallstones, striated thickened wall (> 3.5–4 mm), expanded gallbladder, pericholecystic fluid, localised sensitivity (sonographic Murphy sign) and the presence of sludge (*angl.* sludge) in the gallbladder. In addition to characteristic clinical presentation, at least two signs should be observed; the patient had at least four (1,27,28).

Although the pathogenesis of AAC following EBV infection is not fully known, two mechanisms are mentioned in literature: systemic inflammation activity and/or cholestasis (25,27,29,30). The crucial role of systemic inflammation is inferred in the analysis of clinical cases of AAC published by 2016 by Kottanattu et al. (31), where laboratory testing had a cholestatic pattern was reported in the laboratory test of only one out of 37 patients (25). Systemic inflammation mechanism can also explain other complications of IM, such as acute pancreatitis (31).

However, substances in the bile, such as  $\beta$ -glucuronidase and lysophosphatidylcholine, can directly cause damage of gallbladder mucosa, release of proinflammatory cytokines and development of cholecystitis (5,27,32-34). Additionally, lymphadenitis with extrinsic obstruction of the cystic duct, direct damage of hepatocytes caused by EBV-infected cytotoxic lymphocytes and genetic polymorphism of the enzymes assisting in the synthesis

and transport of bile acids are thought to contribute to the development within liver cholestasis (1,5,34-36). This would explain a more difficult course of infection in patients with Gilbert syndrome with homozygous or heterozygous mutation UGT1A1\*28, which was described by Attilakos et al (11). We did not pursue genetic testing of our patient. Oestrogen is also considered to play a significant role in the development of AAC by promoting the production of proinflammatory mediators, which would explain the fact that most reported cases are women (12,34,37).

With a single exception, AAC was treated conservatively with parenteral rehydration, analgesic therapy and nutrition support (7,10,26). In most cases, after diagnosing AAC, treatment with a broad-spectrum antibiotic or a combination of antibiotics, such as amoxicillin with clavulanic acid or a combination of ceftazidime, gentamicine and metronidazole (7,10,26). However, after reviewing both paediatric and adult cases, Agergaard et al (38) established that disease did not progress more unfavourably even when no antibiotic was introduced. Therefore, with AAC diagnosis following EBV the individual decision on whether to introduce antibiotic is left to the physician.

Our patient had elevated anti-CMV IgM titres and more expressed anti-CMV IgG antibodies determined with CLIA method, which could point to concurrent subacute infection with CMV virus. According to available literature, clinical presentation of IM in case of concurrent infection with EBV and CMV is atypical, more intensive and complex, particularly in adolescents (39). However, lowered immunity as the result of lower relationship between CD4/CD with infection with EBV could lead to reactivation of a latent CMV infection (39-41). Moreover,

Nishikawa et al. established that acute infection with EBV can lead to cross-reactivity with the synthesis of anti-M protein antibodies *angl.* of other herpes viruses, one of which is CMV (42). As we did not choose to further diagnose potential CMV infection of the patient, we cannot reliably interpret serology results.

Microbiologic testing of the patient's stool sample indicated HP-positive antigen. While HP is mentioned in literature as an etiological factor for the development of acute and chronic cholecystitis. We failed to establish a link between AAC and HP in available literature (43,44,45,46).

## 4 Conclusion

AAC is the most common form of cholecystitis in paediatric population. In immunocompetent children, the disease of most often of viral etiology, generally caused by EBV (1). In case of suspected IM presented with severe pain, an abdominal ultrasound and testing for liver function biomarkers should be performed. Usually, the disease is treated symptomatically and has a favourable outcome. While opinion on the need to introduce antibiotic therapy remains divided, a broad-spectrum antibiotic was introduced in most cases presented in literature.

## 5 Consent

We have obtained the consent of the patient, who had already turned 18 years old before the article was submitted.

## References

1. Poddighe D, Tresoldi M, Licari A, Marseglia GL. Acalculous Acute Cholecystitis in Previously Healthy Children: General Overview and Analysis of Pediatric Infectious Cases. *Int J Hepatol*. 2015;2015:459608.
2. Tsakayannis DE, Kozakewich HP, Lillehei CW. Acalculous cholecystitis in children. *J Pediatr Surg*. 1996 Jan;31(1):127–30.
3. Mendonça JA, Marques-Neto JF, Prando P, Appenzeller S. Acute acalculous cholecystitis in juvenile systemic lupus erythematosus. *Lupus*. 2009 May;18(6):561–3.
4. Chen CJ, Huang FC, Tiao MM, Huang YH, Lin LY, Yu HR, et al. Sonographic gallbladder abnormality is associated with intravenous immunoglobulin resistance in Kawasaki disease. *ScientificWorldJournal*. 2012;2012:485758.
5. Barie PS, Eachempati SR. Acute acalculous cholecystitis. *Gastroenterol Clin North Am*. 2010 Jun;39(2):343–57.
6. Yoshie K, Ohta M, Okabe N, Komatsu T, Umemura S. Gallbladder wall thickening associated with infectious mononucleosis. *Abdom Imaging*. 2004 Nov-Dec;29(6):694–5.
7. Prassouli A, Panagiotou J, Vakaki M, Giannatou I, Atilakos A, Garoufi A, et al. Acute acalculous cholecystitis as the initial presentation of primary Epstein-Barr virus infection. *J Pediatr Surg*. 2007 Jan;42(1):E11–3.
8. Lagona E, Sharifi F, Voutsioti A, Mavri A, Markouri M, Attilakos A. Epstein-Barr virus infectious mononucleosis associated with acute acalculous cholecystitis. *Infection*. 2007 Apr;35(2):118–9.
9. Gora-Gebka M, Liberek A, Bako W, Szarszewski A, Kamińska B, Korzon M. Acute acalculous cholecystitis of viral etiology—a rare condition in children? *J Pediatr Surg*. 2008 Jan;43(1):e25–7.
10. Iaria C, Arena L, Di Maio G, Fracassi MG, Leonardi MS, Famulari C, et al. Acute acalculous cholecystitis during the course of primary Epstein-Barr virus infection: a new case and a review of the literature. *Int J Infect Dis*. 2008 Jul;12(4):391–5.
11. Attilakos A, Prassouli A, Hadjigeorgiou G, Lagona E, Kitsiou-Tzeli S, Galla A, et al. Acute acalculous cholecystitis in children with Epstein-Barr virus infection: a role for Gilbert's syndrome? *Int J Infect Dis*. 2009 Jul;13(4):e161–4.
12. Koufakis T, Gabranis I. Another Report of Acalculous Cholecystitis in a Greek Patient with Infectious Mononucleosis: A Matter of Luck or Genetic Predisposition? *Case Reports Hepatol*. 2016;2016:6080832.
13. Cholongitas E, Katsogridakis K, Dasenaki M. Acalculous cholecystitis during the course of acute Epstein-Barr virus infection. *Int J Infect Dis*. 2009 May;13(3):e129–30.
14. Arya SO, Saini A, El-Baba M, Salimnia H, Abdel-Haq N. Epstein Barr virus-associated acute acalculous cholecystitis: a rare occurrence but favorable outcome. *Clin Pediatr (Phila)*. 2010 Aug;49(8):799–804.
15. Nagdev A, Md JW. Bedside ultrasound diagnosis of acalculous cholecystitis from epstein-barr virus. *West J Emerg Med*. 2011 Nov;12(4):481–3.
16. Pelliccia P, Savino A, Cecamore C, Di Marzio D, Chiarelli F, Primavera A, et al. Imaging spectrum of EBV-infection in a young patient. *J Ultrasound*. 2008 Jun;11(2):82–4.
17. Poddighe D, Cagnoli G, Masticci N, Bruni P. Acute acalculous cholecystitis associated with severe EBV hepatitis in an immunocompetent child. *BMJ Case Rep*. 2014 Jan;2014 jan13 1:bcr2013201166.
18. Aydın Teke T, Tanır G, Özel A, Timur ÖM, Ekşioglu AS. A case of acute acalculous cholecystitis during the course of reactive Epstein-Barr virus infection. *Turk J Gastroenterol*. 2013;24(6):571–2.
19. Kim A, Yang HR, Moon JS, Chang JY, Ko JS. Epstein-barr virus infection with acute acalculous cholecystitis. *Pediatr Gastroenterol Hepatol Nutr*. 2014 Mar;17(1):57–60.
20. Fretzayas A, Moustaki M, Attilakos A, Brozou T, Nicolaidou P. Acalculous cholecystitis or biliary dyskinesia for Epstein-Barr virus gallbladder involvement? *Prague Med Rep*. 2014;115(1-2):67–72.
21. Gagneux-Brunon A, Suy F, Pouvaret A, Pillot S, Tarantino E, Bouchet D, et al. Acute acalculous cholecystitis, a rare complication of Epstein-Barr virus primary infection: report of two cases and review. *J Clin Virol*. 2014 Sep;61(1):173–5.
22. Suga K, Shono M, Goji A, Matsuura S, Inoue M, Kawahito M, et al. A case of acute acalculous cholecystitis complicated by primary Epstein-Barr virus infection. *J Med Invest*. 2014;61(3-4):426–9.
23. Majdalani M, Milad N, Sahli Z, Rizk S. Acute acalculous cholecystitis in a Lebanese girl with primary Epstein-Barr viral infection. *BMJ Case Rep*. 2016 Apr;2016:1136.
24. Dunmire SK, Verghese PS, Balfour HH Jr. Primary Epstein-Barr virus infection. *J Clin Virol*. 2018 May;102:84–92.
25. Cameron A, Akilan K, Carr D. Infectious mononucleosis - not always a benign condition: a case report of infectious mononucleosis – associated acute acalculous cholecystitis. *CJEM*. 2018;1:1–3.
26. Rodà D, Huici M, Ricart S, Vila J, Fortuny C, Alsina L. Cholecystitis and nephrotic syndrome complicating Epstein-Barr virus primary infection. *Paediatr Int Child Health*. 2017 Feb;37(1):74–7.
27. Imamoğlu M, Sarihan H, Sari A, Ahmetoğlu A. Acute acalculous cholecystitis in children: diagnosis and treatment. *J Pediatr Surg*. 2002 Jan;37(1):36–9.
28. Mirvis SE, Vainright JR Jr, Nelson AW, Johnston GS, Shorr R, Rodriguez A, et al. The diagnosis of acute acalculous cholecystitis: a comparison of sonography, scintigraphy, and CT. *AJR Am J Roentgenol*. 1986 Dec;147(6):1171–5.
29. Ternberg JL, Keating JP. Acute acalculous cholecystitis. Complication of other illnesses in childhood. *Arch Surg*. 1975 May;110(5):543–7.

30. Parithivel VS, Gerst PH, Banerjee S, Parikh V, Albu E. Acute acalculous cholecystitis in young patients without predisposing factors. *Am Surg*. 1999 Apr;65(4):366–8.
31. Kottanattu L, Lava SA, Helbling R, Simonetti GD, Bianchetti MG, Milani GP. Pancreatitis and cholecystitis in primary acute symptomatic Epstein-Barr virus infection - Systematic review of the literature. *J Clin Virol*. 2016 Sep;82:51–5.
32. Kouroumalis E, Hopwood D, Ross PE, Milne G, Bouchier IA. Gallbladder epithelial acid hydrolases in human cholecystitis. *J Pathol*. 1983 Feb;139(2):179–91.
33. Neiderhiser DH. Acute acalculous cholecystitis induced by lysophosphatidylcholine. *Am J Pathol*. 1986 Sep;124(3):559–63.
34. Yesilbag Z, Karadeniz A, Kaya FO. Case Report Acute Acalculous Cholecystitis: A Rare Presentation of Primary Epstein-Barr Virus Infection in Adults — Case Report and Review of the Literature. 2017;5790102.
35. Huffman JL, Schenker S. Acute acalculous cholecystitis: a review. *Clin Gastroenterol Hepatol*. 2010 Jan;8(1):15–22.
36. Krawczyk M, Grünhage F, Langhirt M, Bohle RM, Lammert F. Prolonged cholestasis triggered by hepatitis A virus infection and variants of the hepatocanalicular phospholipid and bile salt transporters. *Ann Hepatol*. 2012 Sep-Oct;11(5):710–4.
37. Myers SI. The role of eicosanoids in experimental and clinical gallbladder disease. *Prostaglandins Leukot Essent Fatty Acids*. 1992 Mar;45(3):167–80.
38. Agergaard J, Larsen CS. Acute acalculous cholecystitis in a patient with primary Epstein-Barr virus infection: a case report and literature review. *Int J Infect Dis*. 2015 Jun;35:67–72.
39. Dumitra S, Crişan C, Pilat L. Clinical aspects in Epstein-Barr and cytomegalic virus co-infection in children. *Jurnalul Pediatriei*. 2015;XVIII:71–2.
40. Choi EH, Lee HJ, Kim SJ, Eun BW, Kim NH, Lee JA, et al. The association of newly identified respiratory viruses with lower respiratory tract infections in Korean children, 2000-2005. *Clin Infect Dis*. 2006 Sep;43(5):585–92.
41. Chan KH, Luo RX, Chen HL, Ng MH, Seto WH, Peiris JS. Development and evaluation of an Epstein-Barr virus (EBV) immunoglobulin M enzyme-linked immunosorbent assay based on the 18-kilodalton matrix protein for diagnosis of primary EBV infection. *J Clin Microbiol*. 1998 Nov;36(11):3359–61.
42. Nishikawa J, Funada H, Miyazaki T, Fujinami H, Miyazono T, Murakami J, et al. Infectious mononucleosis with atypical manifestations accompanied by transient IgM antibody response for cytomegalovirus. *J Infect Chemother*. 2011 Oct;17(5):686–8.
43. Abro AH, Haider IZ, Ahmad S. Helicobacter pylori infection in patients with calculous cholecystitis: a hospital based study. *J Ayub Med Coll Abbottabad*. 2011 Jan-Mar;23(1):30–3.
44. Gunasekaran P, Vinson I. Helicobacter pylori colonization of gallbladder in patients with symptomatic cholelithiasis. *Int Surg J*. 2017;4(7):2194–6.
45. Chen DF, Hu L, Yi P, Liu WW, Fang DC, Cao H. H pylori exist in the gallbladder mucosa of patients with chronic cholecystitis. *World J Gastroenterol*. 2007 Mar;13(10):1608–11.
46. Backert S, Tegtmeyer N, Oyarzabal OA, Osman D, Rohde M, Grützmann R, et al. Unusual Manifestation of Live Staphylococcus saprophyticus, Corynebacterium urinaleomorphum, and Helicobacter pylori in the Gallbladder with Cholecystitis. *Int J Mol Sci*. 2018 Jun;19(7):1826.













